---
layout: default
title: Apis Mellifera Arnica Montana Bellis Perennis Bryo
parent: 僅模型預測 (L5)
nav_order: 359
evidence_level: L5
indication_count: 0
---

# Apis Mellifera Arnica Montana Bellis Perennis Bryo
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Formula: Insufficient Evidence for TxGNN Repurposing Assessment

## One-Sentence Summary

This Evidence Pack describes a 20-ingredient homeopathic combination formula (including Arnica montana, Calendula officinalis, Hypericum perforatum, and Echinacea, among others), with no established original indication and no market authorization in Taiwan.
The TxGNN model was **unable to generate predicted indications** for this candidate, as the multi-component structure without a single DrugBank ID prevents knowledge-graph traversal.
With **0 clinical trials** and **0 publications** attributable to this specific formulation via the TxGNN pipeline, no meaningful repurposing evaluation can be conducted at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not established (no market authorization) |
| Predicted New Indication | None generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — No predictions generated |
| Market Status | Not marketed (Taiwan) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

No new indication was predicted by TxGNN, so this section departs from the standard format to explain the root cause.

This formula lists 20 co-ingredients spanning botanical and mineral sources typically associated with homeopathic preparations for musculoskeletal trauma, bruising, and inflammation — among them Arnica montana, Calendula officinalis, Comfrey root, Ruta graveolens, Hamamelis virginiana, Bryonia alba, and Hypericum perforatum. However, no single DrugBank ID could be assigned to the formula as a whole, which means no drug node exists in the TxGNN knowledge graph for scoring.

TxGNN is architecturally designed to evaluate individual chemical entities or single active pharmaceutical ingredients. A co-listed formula of 20 ingredients — each potentially at homeopathic dilutions — cannot be resolved to a single graph node, making drug–disease traversal impossible under the current pipeline. Until the formula is either (a) decomposed into individually evaluable constituents or (b) matched to a branded product with an established regulatory identifier, TxGNN prediction scores cannot be generated.

---

## Clinical Trial Evidence

Currently no related clinical trials registered through the TxGNN evidence pipeline for this candidate.

> **Note:** Individual constituent herbs such as Arnica montana, Echinacea, and Hypericum perforatum have independent clinical literature, but those studies are not attributable to this specific multi-ingredient formulation and were not retrieved by the pipeline.

---

## Literature Evidence

Currently no related literature available through the TxGNN evidence pipeline for this candidate.

---

## Market Information

This product has no Taiwan market authorization. No NDA or equivalent license records were identified in the TFDA database (query returned 0 results).

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** No DDI data was retrievable, and no package insert warnings or contraindications were available. Several individual components carry known safety signals that would require evaluation in any future assessment — notably Comfrey root (pyrrolizidine alkaloids, hepatotoxicity risk), Goldenseal (CYP inhibition), and Toxicodendron pubescens (contact sensitizer).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This multi-ingredient homeopathic formula lacks a DrugBank ID, has no approved indications, and generated zero TxGNN predictions — making a repurposing evaluation impossible under the current framework without substantial data remediation.

**To proceed, the following is needed:**

- **Identify the branded product name** — If this formula corresponds to a known product (e.g., Traumeel®, Zeel®, or a regional homeopathic brand), re-run the pipeline using that product's regulatory identifier or DrugBank entry
- **Resolve DG001 (Blocking):** Obtain the TFDA or originator package insert to extract approved indications, warnings, and contraindications
- **Resolve DG002 (High):** Determine whether individual active constituents have DrugBank records (e.g., Arnica montana, Hypericum perforatum, Matricaria chamomilla) and evaluate them separately within TxGNN
- **Clarify formulation type:** Confirm whether this is a registered homeopathic medicine, an herbal supplement, or a botanical drug — as regulatory pathway and evidence standards differ substantially
- **Assess individual ingredients:** Components like Hypericum perforatum and Echinacea have published clinical evidence; a constituent-level repurposing analysis may be feasible even if the combined formula cannot currently be processed
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

